Kinnate Biopharma Inc. verkauft seinen in der Entwicklung befindlichen Pan-RAF-Inhibitor, Exarafenib an Pierre Fabre Laboratories

Written by Emily J. Thompson, Senior Investment Analyst

KNTE%

Source: PRnewswire

Updated: Mar 04 2024

0mins

Source: PRnewswire

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Kinnate Biopharma Inc. verkauft seinen in der Entwicklung befindlichen Pan-RAF-Inhibitor, Exarafenib an Pierre Fabre Laboratories

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Dogecoin Surges 8% to Nearly $0.15 Due to New Senate Crypto Bill Draft

Disney's 17.2 P/E Ratio Suggests Greater Potential than Netflix

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch